☆ 4.5 Article

First-year costs of treating prostate cancer: estimates from SEER-Medicare data

PROSTATE CANCER AND PROSTATIC DISEASES (2009)

期刊

PROSTATE CANCER AND PROSTATIC DISEASES

卷 12, 期 4, 页码 355-360

出版社

NATURE PUBLISHING GROUP

DOI: 10.1038/pcan.2009.21

关键词

prostatic neoplasms; utilization; health-care costs

类别

Oncology Urology & Nephrology

资金

GlaxoSmithKline Inc

向作者/读者索取更多资源

Protocol

Reagent

摘要

Pharmacologic therapies are currently being evaluated for the prevention of prostate cancer (PCa). As additional clinical data become available regarding their benefits and risks, an examination of their economic impact will also be important. The purpose of this study was to estimate mean per patient PCa-related costs during the first year following diagnosis and to examine the extent to which initial therapies are used, by initial cancer stage. Our data show that health-care costs were significant and varied by stage. With average first-year PCa-related costs of US$13 091, prevention strategies have the potential to reduce health-care costs. Prostate Cancer and Prostatic Diseases (2009) 12, 355-360; doi: 10.1038/pcan.2009.21; published online 26 May 2009

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Andrology

Trends in End-of-Life Resource Utilization and Costs among Prostate Cancer Patients from 2006 to 2015: A Nationwide Population-Based Study

Yun-Sok Ha, So-Young Kim, Jae Il Chung, Hoon Choi, Jae Heon Kim, Ho Song Yu, In-Chang Cho, Hyung Joon Kim, Hyun Chul Chung, Jun Sung Koh, Ji Youl Lee, Dong Jin Park, Hyun Tae Kim, Eun Sang Yoo, Tae Gyun Kwon, Kyungchan Min, Wun-Jae Kim, Seok Joong Yun, Jong-Hyock Park

Summary: This study aimed to evaluate end-of-life resource utilization and costs for prostate cancer patients in Korea. The average cost of care during the last year of life increased over a 10-year period, while underutilization of support services was observed, likely due to lack of alternative accommodation for terminal prostate cancer patients.

WORLD JOURNAL OF MENS HEALTH (2021)

添加到收藏夹

Article Oncology

Health care spending in prostate cancer: An assessment of characteristics and health care utilization of high resource-patients

Maxine Sun, Maya Marchese, David F. Friedlander, David-Dan Nguyen, Alexander P. Cole, Sean A. Fletcher, Brandon A. Mahal, Paul L. Nguyen, Toni K. Choueiri, Adam S. Kibel, Quoc-Dien Trinh

Summary: The study revealed that 5% of men diagnosed with prostate cancer accounted for 26% of the total cost incurred, with multimorbidity and advanced disease stage being the primary drivers of high-resource PCa patients.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2021)

添加到收藏夹

Article Oncology

The cost burden of metastatic prostate cancer in the US populations covered by employer-sponsored health insurance

Michal Horny, K. Robin Yabroff, Christopher P. Filson, Zhiyuan Zheng, Donatus U. Ekwueme, Thomas B. Richards, David H. Howard

Summary: This study aimed to provide updated information on the cost to payers attributable to metastatic prostate cancer. By using commercial and Medicare supplemental data from 2009-2019, the authors calculated differences in spending between patients with metastatic prostate cancer and their matched controls. The findings showed a high cost burden attributable to metastatic prostate cancer, and these estimates can enhance the precision of value assessments of clinical and policy approaches to prostate cancer prevention, screening, and treatment.

CANCER (2023)

添加到收藏夹

Article Oncology

Depression, Anxiety, and Patterns of Mental Health Care Among Men With Prostate Cancer Receiving Androgen Deprivation Therapy

Phoebe A. Tsao, Ryan D. Ross, Amy S. B. Bohnert, Bhramar Mukherjee, Megan E. Caram

Summary: In men with prostate cancer receiving ADT, almost half do not receive mental health care, while one in five is introduced to a benzodiazepine. Further improvement is needed in the mental health care for these men.

ONCOLOGIST (2022)

添加到收藏夹

Article Oncology

Out-of-pocket costs for commercially insured patients with localized prostate cancer

Christopher J. D. Wallis, Daniel D. Joyce, Zachary Klaassen, Amy N. Luckenbaugh, Aaron A. Laviana, David Penson, Stacie B. Dusetzina, Daniel A. Barocas

Summary: This study examined the out-of-pocket costs for commercially insured patients with incident prostate cancer in the United States, comparing costs between those who underwent surgery, radiotherapy, and no local treatment. The results showed that patients receiving active treatment with surgery or radiotherapy had significantly higher out-of-pocket costs compared to those who received no treatment, with little difference observed between treatment approaches.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2021)

添加到收藏夹

Article Clinical Neurology

Health care utilization and costs in the years preceding dementia identification

Raj G. Kumar, Evan Bollens Lund, Katherine A. Ornstein, Jing Li, Kenneth E. Covinsky, Amy S. Kelley

Summary: This study shows that individuals with dementia have higher healthcare utilization and costs in the years preceding dementia identification compared to those without dementia. This suggests a greater healthcare burden even before the clinical manifestation and recognition of dementia.

ALZHEIMERS & DEMENTIA (2023)

添加到收藏夹

Review Oncology

Supportive care interventions for men with urological cancers: a scoping review

Mohamad M. Saab, Megan McCarthy, Mike Murphy, Katarina Medved, Maria O'Malley, Richard M. Bambury, Jack P. Gleeson, Brendan Noonan

Summary: This study aimed to identify supportive care interventions for men with urological cancers. Thirty studies were included, with 10 categories of interventions identified. Multicomponent, cognitive-behavioural, telephone and web-based, physical activity/exercise-based, and rehabilitative interventions showed great promise in improving various outcomes, but the improvements were often short-lived.

SUPPORTIVE CARE IN CANCER (2023)

添加到收藏夹

Article Urology & Nephrology

Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States

Charles J. Ryan, Xuehua Ke, Marie-Helene Lafeuille, Hela Romdhani, Frederic Kinkead, Patrick Lefebvre, Allison Petrilla, Zul Pulungan, Seung Kim, Denise M. D'Andrea, Peter Francis, Stephen J. Freedland

Summary: This study provides a contemporary assessment of the treatment patterns, health care resource utilization, and costs among metastatic castration-sensitive prostate cancer patients in the U.S. The study found limited use of newer therapies that improve survival in men with mCSPC in the U.S., and substantial increases in health care resource utilization and costs after onset of metastasis.

JOURNAL OF UROLOGY (2021)

添加到收藏夹

Article Urology & Nephrology

Does post prostatectomy decipher score predict biochemical recurrence and impact care?

Christine White, Ilene Staff, Tara McLaughlin, Joseph Tortora, Kevin Pinto, Akshay Gangakhedkar, Alison Champagne, Joseph Wagner

Summary: The study focused on evaluating the ability of the Decipher test to predict early biochemical recurrence after radical prostatectomy, showing that high-risk Decipher scores were associated with shorter time to biochemical recurrence and receipt of salvage treatment.

WORLD JOURNAL OF UROLOGY (2021)

添加到收藏夹

Article Urology & Nephrology

The Association Between Income Status and Treatment Selection for Prostate Cancer in a Universal Health Care System: A Population-Based Analysis

Justin D. Oake, Oksana Harasemiw, Navdeep Tangri, Thomas W. Ferguson, Jeff W. Saranchuk, Rahul K. Bansal, Darrel E. Drachenberg, Jasmir G. Nayak

Summary: In a universal healthcare system, there is a correlation between income level and the treatment choice for localized prostate cancer, with patients of higher income levels more likely to undergo radical prostatectomy. This study highlights the impact of socioeconomic status on treatment decisions in a healthcare setting.

JOURNAL OF UROLOGY (2021)

添加到收藏夹

Article Urology & Nephrology

Out-of-Pocket Cost Burden Associated With Contemporary Management of Advanced Prostate Cancer Among Commercially Insured Patients

Daniel D. Joyce, Vidit Sharma, David H. Jiang, Holly K. Van Houten, Lindsey R. Sangaralingham, Bijan J. Borah, Eugene D. Kwon, David F. Penson, Stacie B. Dusetzina, Jon C. Tilburt, Stephen A. Boorjian

Summary: This study evaluated the patient-level factors associated with out-of-pocket costs for advanced prostate cancer treatment options. The findings showed that patients receiving novel hormonal therapy had significantly higher treatment-related out-of-pocket costs. Older age, Black race, lower comorbidity scores, and lower household income were associated with higher treatment-related out-of-pocket costs.

JOURNAL OF UROLOGY (2022)

添加到收藏夹

Article Urology & Nephrology

Coping Mechanisms for Financial Toxicity Among Patients With Metastatic Prostate Cancer: A Survey-based Assessment

Daniel D. D. Joyce, Phillip J. J. Schulte, Eugene D. D. Kwon, Stacie B. B. Dusetzina, Kelvin A. A. Moses, Vidit Sharma, David F. F. Penson, Jon C. C. Tilburt, Stephen A. A. Boorjian

Summary: Through patient surveys, this study found that patients with metastatic prostate cancer and high financial toxicity were more likely to decrease spending on basic goods and leisure activities, as well as use savings to pay for their treatment. Understanding the impact of financial toxicity on patients' lives is crucial for decision-making and intervention strategies.

JOURNAL OF UROLOGY (2023)

添加到收藏夹

Article Oncology

Treatment Patterns, Health Care Resource Utilization, and Cost in Patients with Myelofibrosis in the United States

Ronda Copher, Arianna Kee, Aaron Gerds

Summary: Myelofibrosis results in increased resource utilization and costs for patients and the US healthcare system. This study provides insights into treatment patterns, healthcare resource utilization, and costs associated with myelofibrosis, particularly in patients treated with ruxolitinib.

ONCOLOGIST (2022)

添加到收藏夹

Article Oncology

Race-specific prostate cancer outcomes in a cohort of military health care beneficiaries undergoing surgery: 1990-2017

Nathan Oehrlein, Samantha A. Streicher, Huai-Ching Kuo, Avinash Chaurasia, Jacob McFadden, Darryl Nousome, Yongmei Chen, Sean P. Stroup, John Musser, Timothy Brand, Christopher Porter, Inger L. Rosner, Gregory T. Chesnut, Kayla C. Onofaro, Timothy R. Rebbeck, Anthony D'Amico, Grace Lu-Yao, Jennifer Cullen

Summary: This study found that African American patients had a shorter survival time after prostate cancer treatment, but no significant difference was observed between African American and Caucasian American patients in the time from biochemical recurrence to metastasis and metastasis to overall death in an equal access healthcare setting.

CANCER MEDICINE (2022)

添加到收藏夹

Article Geriatrics & Gerontology

Health Care Costs and Utilization Predictions by the Skilled Nursing Facility Readmission Risk Instrument

Anupam Chandra, Sue L. Visscher, Kandace A. Lackore, Rajeev Chaudhry, Paul Y. Takahashi, Gregory J. Hanson, Bijan J. Borah

Summary: This study evaluated the relationship between 30-day health care costs and hospital readmissions based on the SNFRR instrument, finding a positive correlation between SNFRR scores and costs/readmission rates. The SNFRR instrument accurately predicted costs and readmission risk for post-acute care patients, suggesting its potential for categorizing patients for preemptive interventions. Further research is needed to validate its effectiveness in different institutions and geographic areas.

JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION (2021)

添加到收藏夹

暂无数据

暂无数据

© Peeref 2019-2024. All rights reserved.